Clinical manifestations are complex and often involve multi-systemic burdens. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical manifestations, imaging inspections, laboratory tests and pathological activation.
The platform can help to align national and international authorities with teams of experts to provide accurate diagnoses and treatment regimens. In recent years, with the development of therapeutic, immune-regulated therapy and precision medicine, many previously difficult-to-treat genetic metabolic diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adaptation to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of CblC disease. The platform serves a team of internationally authoritative experts in the field of genetic metabolism in China's international medical service system, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of changes in conditions and treatment effects.